Developer docs
API playgroundTry for free, no card

Search company profiles

Trace Biosciences

Full company profile

uuid002iylq

Namestring
Trace Biosciences
Legal namestring
Trace Biosciences
Websiteurl
trace-bio.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Trace Biosciences is a clinical-stage biotechnology company developing nerve-specific near-infrared fluorescent imaging agents that enable real-time visualization of peripheral nerves during surgery. Its technology platform, branded NerveTrace, comprises small-molecule fluorophores that selectively bind peripheral nerves and emit fluorescence in the NIR window (650–900 nm), allowing surgeons to see nerves even when buried beneath tissue and blood. The platform has been built from a proprietary library of 400+ candidates refined over more than a decade of research originating at Oregon Health & Science University, and is compatible with existing fluorescence-guided surgical imaging systems from Intuitive Surgical, Olympus, and Zeiss. The lead candidate, NerveTrace Dx (LGW16-03), received FDA IND clearance in February 2026, with Phase I clinical studies planned to initiate in orthopedic surgery and subsequently expand across urology, colorectal, head and neck, neurosurgery, and reconstructive procedures where nerve injury risk ranges from 14% to 85%.

The company is pre-revenue and operates an enterprise direct-sales GTM motion targeting hospitals and surgical centers post-FDA approval. To date, the agents have been validated in over 50 collaborative studies with clinical and industry partners, and the technology underpins a $31.3M ARPA-H Cancer Moonshot program focused on 3D dual-color mapping of nerves and vasculature. Beyond the lead asset, the pipeline includes NerveTrace Total (extended pharmacokinetics for PNS/CNS applications) and NerveTrace 800 (an indocyanine green-compatible formulation), positioning NerveTrace as a platform that can both feed and leverage AI-driven anatomical mapping systems.

Trace Biosciences is headquartered in Beaverton, Oregon, was founded in 2020 by OHSU scientists Connor Barth, PhD (CEO), Summer Gibbs, PhD (CSO), and Lei Wang, PhD (CTO), and has raised more than $9 million across pre-seed and grant funding from ARPA-H, NIH (NCI, NINDS), NSF, Oregon State Treasury, ONAMI, Elevate Capital, and SciFounders. The team of approximately 15 members includes senior leadership with 25–30+ years of experience in CMC, toxicology, and clinical operations, several of whom have contributed to six or more FDA approvals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBeaverton, United States
HQ citystring
Beaverton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nerve-specific imaging agents, fluorescence-guided surgery, near-infrared fluorophores, intraoperative nerve visualization, surgical imaging diagnostics
Industry4 codes
PRIMARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAG
Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHAEAL
Surgical Navigation, Robotics & Patient-Matched Instrumentation (Ortho/Spine)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLACAGAJ
Surgical, Perioperative & ERAS Pathway Tools
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Surgical Imaging Agents
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Nerve Trace Imaging Agents
TypeOne Time License
Description

Pre-revenue clinical stage. The company is developing nerve-specific fluorescent imaging agents for surgical applications. Revenue will be generated through sale of imaging agents to hospitals and surgical centers following FDA approval.

trace-bio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1NerveTrace
Description

Targeted imaging platform technology that enables real-time visualization of nerves during surgery using near-infrared fluorescent imaging agents.

trace-bio.com
+3 more records
Core offering1 text field

Trace Biosciences develops and is preparing to commercialize nerve-specific near-infrared fluorescent imaging agents that surgeons administer intraoperatively to visualize peripheral nerves in real time during surgery. The company's pipeline — anchored by the IND-cleared NerveTrace Dx (LGW16-03), plus NerveTrace Total and NerveTrace 800 — enables fluorescence-guided surgery using existing clinical imaging systems, and provides ground-truth data to power AI-guided anatomical navigation. The company is pre-revenue and clinical-stage, with Phase I trials planned in orthopedic surgery and expansion planned across urologic, colorectal, head & neck, and neurosurgical indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 25M nerve injuries occur worldwide annually with 108M patients at risk
+3 more records
Product overview1 text field

Trace Biosciences offers the Nerve Trace technology platform, a unified portfolio of nerve-specific near-infrared fluorescent imaging agents for fluorescence-guided surgery. The platform includes three distinct clinical-stage products: NerveTrace Dx (IND approved, for rapid nerve damage assessment in orthopedic/reconstructive/head & neck surgery), NerveTrace Total (high contrast agent for PNS/CNS with extended PK for prostatectomy/brain & spine surgery), and NerveTrace 800 (ICG-compatible agent for colorectal/prostatectomy/hysterectomy). All products are small-molecule fluorophores that selectively bind nerves and emit near-infrared fluorescence, enabling real-time intraoperative nerve visualization across clinical imaging systems. The platform has emerged from 400+ candidate compounds tested in multi-species surgical models.

Product and service3 records
1NerveTrace Dx (LGW16-03)
CategoryClinical-stage nerve-specific fluorescent imaging agent
Description

A nerve-specific near-infrared fluorescent imaging agent (LGW16-03) that selectively binds peripheral nerves and emits fluorescence enabling rapid nerve damage assessment. IND-cleared for first-in-human clinical studies, with initial Phase I/II trials planned in orthopedic, reconstructive, and head & neck surgery.

2NerveTrace Total
CategoryPipeline nerve-specific fluorescent imaging agent
Description

A nerve-specific imaging agent providing high contrast in both peripheral nervous system (PNS) and central nervous system (CNS) tissues with extended pharmacokinetics, designed for prostatectomy, brain & skull base, and spine surgical procedures.

3NerveTrace 800
CategoryPipeline nerve-specific fluorescent imaging agent
Description

A nerve-specific imaging agent designed for compatibility with clinical imaging systems that use indocyanine green (ICG), targeted for colorectal surgery, prostatectomy, and hysterectomy procedures.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial partner for nerve imaging agent studies. Dartmouth is participating in the ARPA-H program for precision tumor removal using Trace's imaging technology.

2Industry & Clinical Partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Trace Biosciences has partnered with top industry and clinical institutions worldwide. To date, agents have been validated in over 50 collaborative studies across all surgical specialties including orthopedic, urology, colorectal, and plastic surgery.

trace-bio.com
3OHSU (Oregon Health & Science University)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Origin of Trace Biosciences technology through co-founders Summer Gibbs and Connor Barth's academic research. Deep academic-industry partnership for clinical translation of nerve imaging technology.

trace-bio.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global medical device leader with the SPY/Novadaq fluorescence-guided surgery platform. Comparable because Stryker is the dominant player in intraoperative fluorescence imaging and could either integrate or compete with Trace's nerve-specific agents.

TypeOthers
Description

Large life sciences and diagnostics tools provider offering fluorescent reagents and imaging consumables. Comparable as an adjacent enabling vendor in the fluorescent imaging ecosystem rather than a direct surgical agent competitor.

3Lumiprobe
TypeDirect peer
Description

Manufacturer of fluorescent dyes and probes, including NIR and reactive fluorophores used in biomedical imaging. Comparable as a supplier/peer of small-molecule fluorescent agents that could be repurposed or compete in research-grade surgical imaging.

4Avelas Biosciences
TypeDirect peer
Description

Clinical-stage developer of fluorescent imaging agents designed to light up cancer and critical anatomy during surgery. Comparable because Avelas is pursuing a similar playbook of tissue-targeted fluorescent agents for real-time surgical guidance.

TypeDirect peer
Description

Developer of targeted NIR fluorescent imaging agents for surgical and oncology applications. Comparable because Curadel is among the closest direct competitors developing disease/tissue-targeted fluorescent probes for intraoperative use.

6Carl Zeiss Meditec
TypeBroad incumbent
Description

Provider of surgical microscopy and fluorescence imaging systems used in operating rooms. Comparable as one of Trace's named integration partners and a broad incumbent in intraoperative optical imaging.

TypeBroad incumbent
Description

Maker of the da Vinci surgical robot with integrated Firefly ICG fluorescence imaging. Comparable as both a hardware platform compatible with Trace's NerveTrace agents and a potential entrant into targeted nerve imaging.

TypeDirect peer
Description

Developer of NIR fluorescent dyes and IRDye reagents used across life science and preclinical imaging. Comparable as a peer with deep NIR fluorophore chemistry expertise relevant to nerve-targeted agents.

TypeDirect peer
Description

Developer of targeted fluorescent imaging agents and radiopharmaceuticals for surgical and diagnostic use. Comparable as a small-cap peer developing indication-specific fluorescent imaging agents.

TypeBroad incumbent
Description

Endoscopy and surgical imaging systems provider whose fluorescence imaging platforms are compatible with Trace's agents. Comparable as both an integration partner and an established OR imaging incumbent.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Trace Biosciences

Surgical Imaging Agentstrace-bio.com

What Trace Biosciences does

Trace Biosciences is a clinical-stage biotechnology company developing nerve-specific near-infrared fluorescent imaging agents that enable real-time visualization of peripheral nerves during surgery. Its technology platform, branded NerveTrace, comprises small-molecule fluorophores that selectively bind peripheral nerves and emit fluorescence in the NIR window (650–900 nm), allowing surgeons to see nerves even when buried beneath tissue and blood. The platform has been built from a proprietary library of 400+ candidates refined over more than a decade of research originating at Oregon Health & Science University, and is compatible with existing fluorescence-guided surgical imaging systems from Intuitive Surgical, Olympus, and Zeiss. The lead candidate, NerveTrace Dx (LGW16-03), received FDA IND clearance in February 2026, with Phase I clinical studies planned to initiate in orthopedic surgery and subsequently expand across urology, colorectal, head and neck, neurosurgery, and reconstructive procedures where nerve injury risk ranges from 14% to 85%.

The company is pre-revenue and operates an enterprise direct-sales GTM motion targeting hospitals and surgical centers post-FDA approval. To date, the agents have been validated in over 50 collaborative studies with clinical and industry partners, and the technology underpins a $31.3M ARPA-H Cancer Moonshot program focused on 3D dual-color mapping of nerves and vasculature. Beyond the lead asset, the pipeline includes NerveTrace Total (extended pharmacokinetics for PNS/CNS applications) and NerveTrace 800 (an indocyanine green-compatible formulation), positioning NerveTrace as a platform that can both feed and leverage AI-driven anatomical mapping systems.

Trace Biosciences is headquartered in Beaverton, Oregon, was founded in 2020 by OHSU scientists Connor Barth, PhD (CEO), Summer Gibbs, PhD (CSO), and Lei Wang, PhD (CTO), and has raised more than $9 million across pre-seed and grant funding from ARPA-H, NIH (NCI, NINDS), NSF, Oregon State Treasury, ONAMI, Elevate Capital, and SciFounders. The team of approximately 15 members includes senior leadership with 25–30+ years of experience in CMC, toxicology, and clinical operations, several of whom have contributed to six or more FDA approvals.

Trace Biosciences firmographics

Firmographics
Name
Trace Biosciences
Legal name
Trace Biosciences
Website
https://trace-bio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Trace Biosciences industry classification

Industry
Product category
Surgical Imaging Agents
NAICS
Surgical and Medical Instrument Manufacturing (339112), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAG
Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHAEAL
Surgical Navigation, Robotics & Patient-Matched Instrumentation (Ortho/Spine)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLACAGAJ
Surgical, Perioperative & ERAS Pathway Tools
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools

Keywords

  • Nerve-specific imaging agents
  • Fluorescence-guided surgery
  • Near-infrared fluorophores
  • Intraoperative nerve visualization
  • Surgical imaging diagnostics

Where Trace Biosciences is headquartered

Location

Headquarters

HQ city
Beaverton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Trace Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Nerve Trace Imaging Agents: Pre-revenue clinical stage. The company is developing nerve-specific fluorescent imaging agents for surgical applications. Revenue will be generated through sale of imaging agents to hospitals and surgical centers following FDA approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Trace Biosciences product offering

Product offering

Core offering

Trace Biosciences develops and is preparing to commercialize nerve-specific near-infrared fluorescent imaging agents that surgeons administer intraoperatively to visualize peripheral nerves in real time during surgery. The company's pipeline — anchored by the IND-cleared NerveTrace Dx (LGW16-03), plus NerveTrace Total and NerveTrace 800 — enables fluorescence-guided surgery using existing clinical imaging systems, and provides ground-truth data to power AI-guided anatomical navigation. The company is pre-revenue and clinical-stage, with Phase I trials planned in orthopedic surgery and expansion planned across urologic, colorectal, head & neck, and neurosurgical indications.

Product overview

Trace Biosciences offers the Nerve Trace technology platform, a unified portfolio of nerve-specific near-infrared fluorescent imaging agents for fluorescence-guided surgery. The platform includes three distinct clinical-stage products: NerveTrace Dx (IND approved, for rapid nerve damage assessment in orthopedic/reconstructive/head & neck surgery), NerveTrace Total (high contrast agent for PNS/CNS with extended PK for prostatectomy/brain & spine surgery), and NerveTrace 800 (ICG-compatible agent for colorectal/prostatectomy/hysterectomy). All products are small-molecule fluorophores that selectively bind nerves and emit near-infrared fluorescence, enabling real-time intraoperative nerve visualization across clinical imaging systems. The platform has emerged from 400+ candidate compounds tested in multi-species surgical models.

Differentiator

Problem solved

Functional benefit

Brands

  • NerveTrace: Targeted imaging platform technology that enables real-time visualization of nerves during surgery using near-infrared fluorescent imaging agents.
  • NerveTrace Dx
  • NerveTrace Total
  • NerveTrace 800

Products and services

  • NerveTrace Dx (LGW16-03) A nerve-specific near-infrared fluorescent imaging agent (LGW16-03) that selectively binds peripheral nerves and emits fluorescence enabling rapid nerve damage assessment. IND-cleared for first-in-human clinical studies, with initial Phase I/II trials planned in orthopedic, reconstructive, and head & neck surgery.
  • NerveTrace Total A nerve-specific imaging agent providing high contrast in both peripheral nervous system (PNS) and central nervous system (CNS) tissues with extended pharmacokinetics, designed for prostatectomy, brain & skull base, and spine surgical procedures.
  • NerveTrace 800 A nerve-specific imaging agent designed for compatibility with clinical imaging systems that use indocyanine green (ICG), targeted for colorectal surgery, prostatectomy, and hysterectomy procedures.

Quantifiable outcome

  • 25M nerve injuries occur worldwide annually with 108M patients at risk
  • +3 more outcomes

Companies that use Trace Biosciences

Customer profile

Named customers2 records

Segments5 records

Ideal customer profiles3 records

Trace Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability8 records

Feature4 records

Trace Biosciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Dartmouth HealthcoreStrategic or Co-development PartnerClinical trial partner for nerve imaging agent studies. Dartmouth is participating in the ARPA-H program for precision tumor removal using Trace's imaging technology.
  • Industry & Clinical PartnerscoreStrategic or Co-development PartnerTrace Biosciences has partnered with top industry and clinical institutions worldwide. To date, agents have been validated in over 50 collaborative studies across all surgical specialties including orthopedic, urology, colorectal, and plastic surgery.
  • OHSU (Oregon Health & Science University)coreStrategic or Co-development PartnerOrigin of Trace Biosciences technology through co-founders Summer Gibbs and Connor Barth's academic research. Deep academic-industry partnership for clinical translation of nerve imaging technology.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Trace Biosciences competitors and assessment

Company assessment

Broad incumbents

  • Stryker: Global medical device leader with the SPY/Novadaq fluorescence-guided surgery platform. Comparable because Stryker is the dominant player in intraoperative fluorescence imaging and could either integrate or compete with Trace's nerve-specific agents.
  • Carl Zeiss Meditec: Provider of surgical microscopy and fluorescence imaging systems used in operating rooms. Comparable as one of Trace's named integration partners and a broad incumbent in intraoperative optical imaging.
  • Intuitive Surgical: Maker of the da Vinci surgical robot with integrated Firefly ICG fluorescence imaging. Comparable as both a hardware platform compatible with Trace's NerveTrace agents and a potential entrant into targeted nerve imaging.
  • Olympus Medical: Endoscopy and surgical imaging systems provider whose fluorescence imaging platforms are compatible with Trace's agents. Comparable as both an integration partner and an established OR imaging incumbent.

Others

  • PerkinElmer: Large life sciences and diagnostics tools provider offering fluorescent reagents and imaging consumables. Comparable as an adjacent enabling vendor in the fluorescent imaging ecosystem rather than a direct surgical agent competitor.

Direct peers

  • Lumiprobe: Manufacturer of fluorescent dyes and probes, including NIR and reactive fluorophores used in biomedical imaging. Comparable as a supplier/peer of small-molecule fluorescent agents that could be repurposed or compete in research-grade surgical imaging.
  • Avelas Biosciences: Clinical-stage developer of fluorescent imaging agents designed to light up cancer and critical anatomy during surgery. Comparable because Avelas is pursuing a similar playbook of tissue-targeted fluorescent agents for real-time surgical guidance.
  • Curadel (Fluopticon): Developer of targeted NIR fluorescent imaging agents for surgical and oncology applications. Comparable because Curadel is among the closest direct competitors developing disease/tissue-targeted fluorescent probes for intraoperative use.
  • LI-COR Biosciences: Developer of NIR fluorescent dyes and IRDye reagents used across life science and preclinical imaging. Comparable as a peer with deep NIR fluorophore chemistry expertise relevant to nerve-targeted agents.
  • Molecular Targeting Technologies (MTTI): Developer of targeted fluorescent imaging agents and radiopharmaceuticals for surgical and diagnostic use. Comparable as a small-cap peer developing indication-specific fluorescent imaging agents.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Trace Biosciences social profiles

Digital presence

Trace Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Trace Biosciences leadership team

Management profile

Number of profiles

Profiles8 records

Trace Biosciences funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Trace Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trace Biosciences

What does Trace Biosciences do?

Trace Biosciences develops and is preparing to commercialize nerve-specific near-infrared fluorescent imaging agents that surgeons administer intraoperatively to visualize peripheral nerves in real time during surgery. The company's pipeline — anchored by the IND-cleared NerveTrace Dx (LGW16-03), plus NerveTrace Total and NerveTrace 800 — enables fluorescence-guided surgery using existing clinical imaging systems, and provides ground-truth data to power AI-guided anatomical navigation. The company is pre-revenue and clinical-stage, with Phase I trials planned in orthopedic surgery and expansion planned across urologic, colorectal, head & neck, and neurosurgical indications.

Is Trace Biosciences a public or private company?

Trace Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Trace Biosciences founded?

Trace Biosciences was founded in 2020. It employs 11 to 50 people.

Where is Trace Biosciences based?

Trace Biosciences is headquartered in Beaverton, United States, in the North America region.

How does Trace Biosciences make money?

One revenue line is on record: nerve Trace Imaging Agents.

Who are Trace Biosciences's main competitors?

Broad incumbents on record are Stryker, Carl Zeiss Meditec, Intuitive Surgical and Olympus Medical. PerkinElmer is listed as an others. Direct peers are Lumiprobe, Avelas Biosciences, Curadel (Fluopticon), LI-COR Biosciences and Molecular Targeting Technologies (MTTI).

Does Trace Biosciences have an API?

No public API is recorded for Trace Biosciences.

What industry is Trace Biosciences in?

Trace Biosciences's product category is Surgical Imaging Agents. Its primary akta.pro industry code is HLAHADAH, Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence), with a secondary code of HLAHADAG, Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Trace Biosciences Raises Strategic Investment From AxogenTrace Biosciences, a clinical-stage biotechnology company, has received a strategic investment from Axogen, Inc. as part of its Series A financing round, with additional investors expected to join. The company's lead candidate, Nerve Trace Dx, a near-infrared fluorescence imaging technology for real-time nerve visualization during surgery, received FDA clearance in December 2025 and has begun Phase I clinical trials. Proceeds from the investment will support Phase II and III clinical trials toward a New Drug Application.AijournTrace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging TechnologyTrace Biosciences, a clinical-stage biotechnology company developing nerve-targeted imaging agents, announced it has received a strategic investment from Axogen, Inc. as part of its Series A financing round. The investment will support advancement of Nerve Trace Dx through Phase II and III clinical trials toward a New Drug Application, following the technology's FDA IND clearance in December 2025 and ongoing Phase I trial. Axogen, the global leader in surgical solutions for peripheral nerve function, stated the investment aligns with its mission to make restoration of peripheral nerve function an expected standard of care.Investing.comAxogen invests in Trace Biosciences’ nerve imaging technology By Investing.comAxogen Inc. made a strategic investment in Trace Biosciences as part of its Series A financing round to support development of Nerve Trace, a near-infrared fluorescence imaging technology for nerve visualization during surgery. Trace's lead candidate, Nerve Trace Dx, received FDA clearance in December 2025 and has begun Phase I clinical trials, with plans to use the investment proceeds to fund Phase II and III trials toward a New Drug Application. Additional investors are expected to join the Series A round, though specific terms and total funding amounts were not disclosed.PR NewswireTrace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging TechnologyTrace Biosciences, a clinical-stage biotechnology company, announced it received a strategic investment from Axogen, Inc. as part of its Series A financing round. The investment will fund advancement of Nerve Trace, a near-infrared fluorescence imaging technology for real-time nerve visualization during surgery, through Phase II and III clinical trials toward a New Drug Application. Trace's lead candidate Nerve Trace Dx received FDA IND clearance in December 2025 and has begun Phase I trials evaluating safety and feasibility in surgical patients.Stock TitanTrace Biosciences Receives Axogen Investment for TrialsTrace Biosciences, a clinical-stage biotechnology company based in Portland, Oregon, announced a strategic investment from Axogen, Inc. to advance its Nerve Trace near-infrared fluorescence imaging technology through clinical development. The investment is part of Trace's Series A financing round, with Nerve Trace Dx having received FDA IND clearance in December 2025 and currently in Phase I trials, and proceeds intended to support Phase II and III trials toward a New Drug Application. The partnership aligns with Axogen's mission of advancing peripheral nerve function restoration as a standard of care in surgery.Stock TitanAxogen Q2 Earnings: Revenue Up 23.1%; 2026 Guide 24%+Axogen reported Q2 2026 revenue of $69.7 million, a 23.1% increase year-over-year driven by broad-based growth across Extremities, Oral Maxillofacial & Head and Neck, and Breast markets. The company raised its full-year revenue guidance to at least 24% growth (or $279 million) and expects positive free cash flow for 2026, despite reporting a GAAP net loss of $1.5 million due to a one-time debt extinguishment charge. Axogen also acquired a minority ownership stake in Trace Biosciences to support development of nerve-specific imaging technology.GlobeNewswireAxogen, Inc. Reports Second Quarter 2026 Financial ResultsAxogen, Inc. reported second quarter 2026 revenue of $69.7 million, a 23.1% increase year-over-year, though the company posted a GAAP net loss of $1.5 million compared to net income of $0.6 million in Q2 2025, impacted by a $16.8 million loss on debt extinguishment. Adjusted net income was $7.3 million ($0.12 per share), and the company raised its 2026 full-year revenue guidance to at least $279 million, representing at least 24% growth. Axogen also acquired a minority ownership stake in Trace Biosciences to support development of nerve-specific imaging technology.citybizTrace Biosciences Secures Strategic Investment From Axogen to Advance Nerve Imaging TrialsTrace Biosciences secured a strategic investment from Axogen to fund Phase II and III clinical trials for its Nerve Trace imaging technology. The capital will support development toward an FDA NDA for Nerve Trace Dx, which was cleared for an IND in December 2025. The partnership aims to make nerve visualization a routine part of surgery.FinSMEsTrace Biosciences Receives Investment From AxogenTrace Biosciences, a clinical-stage biotech developing nerve-targeted imaging agents, received an undisclosed strategic investment from Axogen as part of its Series A financing. The company plans to use the funds to support Phase II and III clinical trials toward a New Drug Application. Its lead candidate, Nerve Trace Dx, is in Phase I trials after FDA clearance in December 2025.BioSpaceTrace Biosciences Announces FDA IND Clearance for First Nerve-Specific Imaging AgentTrace Biosciences has received FDA IND clearance for LGW16-03, its first nerve-specific near-infrared fluorescent imaging agent designed to help surgeons visualize peripheral nerves in real time during surgery to reduce accidental nerve injuries. The company plans to initiate Phase I clinical studies later this year, initially evaluating safety and feasibility in orthopedic surgery patients. This represents the first clinical program within Trace's broader nerve-targeted imaging platform aimed at fluorescence-guided surgery and diagnostic applications.